SEARCH

SEARCH BY CITATION

References

  • 1
    Jalan R. Acute liver failure: current management and future prospects. J Hepatol 2005; 42( Suppl): S115S123.
  • 2
    Verbeke L, Nevens F, Laleman W. Bench-to-beside review: Acute-on-chronic liver failure — linking the gut, liver and systemic circulation. Crit Care 2011; 15: 233.
  • 3
    Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif 2002; 20: 252261.
  • 4
    Katoonizadeh A, Laleman W, Verslype C, Wilmer A, Maleux G, Roskams T, et al. Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut 2010; 59: 15611569.
  • 5
    Basto ST, Villela-Nogueira CA, Tura BR, Coelho HS, Ribeiro J, Fernandes ES, et al. Risk factors for long-term mortality in a large cohort of patients wait-listed for liver transplantation in Brazil. Liver Transpl 2011; 17: 10131020.
  • 6
    Catalina MV, Barrio J, Anaya F, Salcedo M, Rincon D, Clemente G, et al. Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure. Liver Int 2003; 23( Suppl 3): 3943.
  • 7
    Sen S, Mookerjee RP, Cheshire LM, Davies NA, Williams R, Jalan R. Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. J Hepatol 2005; 43: 142148.
  • 8
    Laleman W, Wilmer A, Evenepoel P, Elst IV, Zeegers M, Zaman Z, et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006; 10: R108.
  • 9
    Hassanein TI, Tofteng F, Brown RS Jr, McGuire B, Lynch P, Mehta R, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. HEPATOLOGY 2007; 46: 18531862.
  • 10
    Pares A, Deulofeu R, Cisneros L, Escorsell A, Salmeron JM, Caballeria J, et al. Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure. Crit Care 2009; 13: R8.
  • 11
    Pares A, Cisneros L, Salmeron JM, Caballeria L, Mas A, Torras A, et al. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2004; 99: 11051110.
    Direct Link:
  • 12
    Leckie P, Tritto G, Mookerjee R, Davies N, Jones D, Jalan R. ‘Out-patient’ albumin dialysis for cholestatic patients with intractable pruritus. Aliment Pharmacol Ther 2012; 35: 696704.
  • 13
    Pares A, Herrera M, Aviles J, Sanz M, Mas A. Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol 2010; 53: 307312.
  • 14
    Chiu A, Tsoi NS, Fan ST. Use of the molecular adsorbents recirculating system as a treatment for acute decompensated Wilson disease. Liver Transpl 2008; 14: 15121516.
  • 15
    Kantola T, Koivusalo AM, Hockerstedt K, Isoniemi H. Early molecular adsorbents recirculating system treatment of Amanita mushroom poisoning. Ther Apher Dial 2009; 13: 399403.
  • 16
    Wittebole X, Hantson P. Use of the molecular adsorbent recirculating system (MARS) for the management of acute poisoning with or without liver failure. Clin Toxicol (Phila) 2011; 49: 782793.
  • 17
    Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Malago M, et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. HEPATOLOGY 2002; 36: 949958.
  • 18
    Jalan R, Sen S, Steiner C, Kapoor D, Alisa A, Williams R. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol 2003; 38: 2431.
  • 19
    Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6: 277286.
  • 20
    Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. HEPATOLOGY 2001; 33: 464470.
  • 21
    de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005; 43: 167176.
  • 22
    Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403409.
  • 23
    Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 13681377.
  • 24
    Harry R, Auzinger G, Wendon J. The clinical importance of adrenal insufficiency in acute hepatic dysfunction. HEPATOLOGY 2002; 36: 395402.
  • 25
    Sen S, Davies NA, Mookerjee RP, Cheshire LM, Hodges SJ, Williams R, et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl 2004; 10: 11091119.
  • 26
    Kribben A, Gerken G, Haag S, Herget-Rosenthal S, Treichel U, Betz C, et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology 2012; 142: 782789 e783.
  • 27
    Honore PM, Jacobs R, Joannes-Boyau O, De Regt J, Boer W, De Waele E, et al. Septic AKI in ICU patients. diagnosis, pathophysiology, and treatment type, dosing, and timing: a comprehensive review of recent and future developments. Ann Intens Care 2011; 1: 32.
  • 28
    Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296327.
  • 29
    Camus C, Lavoue S, Gacouin A, Compagnon P, Boudjema K, Jacquelinet C, et al. Liver transplantation avoided in patients with fulminant hepatic failure who received albumin dialysis with the molecular adsorbent recirculating system while on the waiting list: impact of the duration of therapy. Ther Apher Dial 2009; 13: 549555.
  • 30
    Evenepoel P, Laleman W, Wilmer A, Claes K, Kuypers D, Bammens B, et al. Prometheus versus molecular adsorbents recirculating system: comparison of efficiency in two different liver detoxification devices. Artif Organs 2006; 30: 276284.
  • 31
    Jalan R, Schnurr K, Mookerjee RP, Sen S, Cheshire L, Hodges S, et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. HEPATOLOGY 2009; 50: 555564.